IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Conditions: Advanced Melanoma Interventions: Biological: IMC-F106C; Biological: Nivolumab; Biological: Nivolumab + Relatlimab Sponsors: Immunocore Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials